文献速递腹部CT

序贯双能CT纵向评估局部进展期胃癌新辅助免疫化疗病理反应

Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer.
PubMed 文献 · Eur Radiol · 2025-04-25

回顾性纳入115例局部进展期胃癌患者,于新辅助免疫化疗前后行双能CT三期增强扫描,以病理肿瘤退缩分级为参考标准。治疗前延迟期碘浓度、动脉期碘浓度变化率及治疗后肿瘤厚度三项指标单独及联合预测非缓解者的AUC分别为0.616、0.625、0.660和0.774,联合指标与无病生存期相关(HR 2.239,95%CI 1.004-4.991,P=0.026)。

要点

  • 治疗前延迟期碘浓度>2.306 mg/mL提示非缓解者,AUC 0.616(95%CI 0.521-0.705)。
  • 动脉期碘浓度变化率≤26.70%提示非缓解者,AUC 0.625(95%CI 0.529-0.713)。
  • 治疗后肿瘤厚度>18.5 mm提示非缓解者,三项指标联合AUC提升至0.774。

核心结论

  • 新辅助免疫化疗前后双能CT定量参数有助于纵向评估局部进展期胃癌的病理反应。
  • 治疗前延迟期碘浓度、动脉期碘浓度变化率和治疗后肿瘤厚度三项参数预测非缓解者的价值相当,联合应用具有增量获益。

研究设计与样本

  • 回顾性研究,纳入2021年1月至2023年12月接受新辅助免疫化疗加胃切除术、且治疗前后均行三期增强双能CT扫描的115例局部进展期胃癌患者。
  • 以病理肿瘤退缩分级为参考标准,将患者分为缓解者(TRG=0+1)和非缓解者(TRG=2+3)。
  • 采用二维自由手绘感兴趣区法获取碘浓度值,分别测量治疗前后动脉期、静脉期、延迟期的碘浓度和标准化碘浓度,并计算变化率ΔIC(%)=(治疗后IC−治疗前IC)/治疗前IC×100%。

诊断标准与关键数值

  • 治疗前延迟期碘浓度>2.306 mg/mL预测非缓解者,AUC 0.616(95%CI 0.521-0.705)。
  • 动脉期碘浓度变化率≤26.70%预测非缓解者,AUC 0.625(95%CI 0.529-0.713)。
  • 治疗后肿瘤厚度>18.5 mm预测非缓解者,AUC 0.660(95%CI 0.565-0.745)。
  • 三项参数联合预测非缓解者的AUC为0.774(95%CI 0.686-0.846)。
  • 联合指标与患者无病生存期相关,风险比HR 2.239(95%CI 1.004-4.991),P=0.026。

临床应用与阅片要点

  • 作者认为,基于治疗前后双能CT的定量参数可用于纵向评估局部进展期胃癌新辅助免疫化疗后的病理反应结局。
  • 作者指出,双能CT是颇具前景的影像技术,在纵向评估该人群新辅助免疫化疗病理反应方面具有额外优势,可能有助于促进更个体化的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To longitudinally evaluate pathologic response outcomes after neoadjuvant immuno-chemotherapy (NICT) for patients with locally advanced gastric cancer (LAGC) using pre- and post-treatment dual-energy CT (DECT).

MATERIALS AND METHODS: Between Jan 2021 and Dec 2023, 115 patients who underwent NICT plus gastrectomy and triple-phase enhanced DECT scans before and after NICT were retrospectively enrolled. Pathologic tumor regression grade (TRG) was the reference standard, patients were labelled as responders (TRG = 0 + 1) and non-responders (TRG = 2 + 3) accordingly. A two-dimensional free-hand region of interest method was adopted to obtain the iodine concentration (IC) values. Pre- and post-NICT IC and normalized IC (nIC) were measured at arterial/venous/delay phase (AP/VP/DP), respectively; their changes [ΔIC (%)] defined as (IC_post-IC_pre)⁄IC_pre × 100% were calculated. Pre- and post-NICT imaging parameters and their changes were compared between different response groups. Non-responders' associated parameters were selected using multivariable logistic regression analysis. Their performances were analyzed by the area under the receiver operating characteristic curve (AUC). Their associations with patient survival were explored by using Kaplan-Meier survival analysis.

RESULTS: ICDP-pre, ΔICAP, thickness-post with cut-off value of > 2.306 mg/mL, ≤ 26.70%, > 18.5 mm, respectively, indicates non-responders with equivalent AUC being 0.616 (95% CI: 0.521-0.705), 0.625 (95% CI: 0.529-0.713), and 0.660 (95% CI: 0.565-0.745). Their combination demonstrated an improved AUC of 0.774 (95% CI: 0.686-0.846) and was associated with patient disease-free survival (DFS) with a hazard ratio being 2.239 (95% CI: 1.004-4.991) (p = 0.026).

CONCLUSION: Pre- and post-NICT DECT-based quantifications are useful for longitudinal assessment of pathologic response outcomes after NICT in LAGC. ICDP-pre, ΔICAP, and thickness-post are equally useful, their combination demonstrated incremental benefit.

KEY POINTS: Question Accurate evaluation of the efficacy of NICT in patients with LAGC remains challenging due to the lack of effective biomarkers. Findings Sequential DECT-based ICDP-pre, ΔICAP, and tumor thickness-post were predictive of TRG status. Their combination demonstrated enhanced performance and was associated with patient DFS. Clinical relevance DECT represents a promising imaging technique with added advantages for longitudinal assessment of pathologic response to NICT in LAGC, potentially facilitating more personalized treatment strategies among this population.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lin X, Xu S, Wang Y, et al. Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer. Eur Radiol. 2025. PMID: 40278873. doi:10.1007/s00330-025-11601-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。